AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:03 2024-04-19 am EDT			5-day change	1st Jan Change
10,946 ^GBX	+0.29%		-1.07%	+3.26%

Apr. 17	AstraZeneca: presents new data at ECCMID	CF
Apr. 17	The market is pinning its hopes on earnings reports

AstraZeneca : Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer

September 18, 2021 at 07:42 am EDT

First HER2-directed therapy to show a strong tumour response in this populationData from HER2-mutant cohort of pivotal DESTINY-Lung01 Phase II trial presented at ESMO and published in The New England Journal of Medicine

Attachments

Original document
Permalink

Disclaimer

AstraZeneca plc published this content on 18 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 September 2021 11:41:02 UTC.

Latest news about AstraZeneca PLC

AstraZeneca: presents new data at ECCMID	Apr. 17	CF
The market is pinning its hopes on earnings reports	Apr. 17
ASTRAZENECA : Receives a Buy rating from JP Morgan	Apr. 17	ZD
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	Apr. 17
Market sentiment sours	Apr. 16
ASTRAZENECA : Deutsche Bank returns to 'Hold	Apr. 16	CF
Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT	Apr. 16	MT
Astrazeneca plc Announces IMFINZI Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial	Apr. 16	CI
ASTRAZENECA : Deutsche Bank drops its Sell rating	Apr. 16	ZD
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca	Apr. 16
RBC raises Admiral; Barclays cuts Phoenix Group	Apr. 16	AN
AstraZeneca: improvements in biliary tract cancer	Apr. 16	CF
AstraZeneca's hails Imfinzi survival data on cancer form	Apr. 16	AN
AstraZeneca's Biliary Tract Cancer Combo Improves Overall Survival in Late-stage Trial	Apr. 16	MT
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors	Apr. 15	CI
AstraZeneca: expects a sharp rise in kidney disease	Apr. 15	CF
ASTRAZENECA : Barclays reiterates its Buy rating	Apr. 15	ZD
Adherium’s Hailie Smartinhaler Secures FDA Approval for Use with AstraZeneca's Airsupra and Breztri Inhalation Devices	Apr. 14	MT
Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...	Apr. 12
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says	Apr. 12	DJ
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs	Apr. 12	MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts	Apr. 12	RE
Fitch Affirms AstraZeneca Rating on Stable Position in Pharmaceutical Sector	Apr. 12	MT
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	Apr. 11	MT
AstraZeneca Executives' Compensation Policy Passes With Low Shareholder Approval	Apr. 11	DJ

Chart AstraZeneca PLC

Duration

Period

More charts

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : AstraZeneca should not be overlooked for long

April 03, 2024 at 10:26 am EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

136 USD

Average target price

162 USD

Spread / Average Target

+19.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+3.26%	211B
ELI LILLY AND COMPANY	+25.06%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-6.30%	351B
MERCK & CO., INC.	+15.19%	317B
ABBVIE INC.	+7.30%	292B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-10.37%	144B
AMGEN INC.	-7.29%	141B
SANOFI	-3.20%	113B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

AstraZeneca : Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer

EPS Revisions